SecBot SecBot
EFFECT ·Filed Jun 11, 2026

FBRX

Forte Biosciences, Inc.
BEARISH
Impact 6/10
Horizonweeks Processed5mo ago SEC9999999995-26-001951
IPO/offering going effective
Actionable Insight ▼ Bearish

The effective shelf creates a persistent overhang. Watch for a takedown announcement (prospectus supplement or 424B), any offering would likely be dilutive given the cash burn rate. The stock may drift lower on uncertainty until the company either draws on the shelf or provides clarity on funding plans.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$17.40
T+0 close · Jun 11, 2026 · via day close
Latest settled
+110.92%
T+20 · $36.70
Vs SPY
+109.03%
α at T+20
Next horizon
T+60
due 2mo ago
  1. T+0 · Jun 11 $17.40entry
  2. T+1 · 5mo ago +0.92%α +0.38% · $17.56
  3. T+5 · 5mo ago +1.09%α +0.66% · $17.59
  4. T+20 · 4mo ago +110.92%α +109.03% · $36.70
  5. T+60 · due 2mo ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Forte Biosciences' universal shelf registration (File No. 333-296425) became effective on June 10, 2026, enabling the company to offer and sell up to $500M in securities. This opens the door for potential capital raises to fund Phase 2 trials and operations, creating a persistent dilution overhang given the company's $344M market cap and accelerating cash burn.

Key Facts

  • Shelf registration on Form S-3 became effective June 10, 2026 (File No. 333-296425).
  • Company registered up to $500M in securities (common, preferred, debt, warrants, units).
  • Market cap is ~$344M; shelf represents ~145% of current market cap.
  • Q1 2026 cash & equivalents fell to $58.2M from $77.0M; net loss was $22.1M.
  • No specific offering announced; shelf enables at-the-market or underwritten offerings at any time.

Financial Impact

Potential dilution of up to ~145% of current market cap if fully utilized; no specific offering announced.

dilutioncash runwayshare count

Risk Factors

  • Imminent equity offering could dilute existing shareholders significantly.
  • Cash burn of ~$22M/quarter suggests shelf will likely be tapped within months.
  • No revenue to offset dilution; all value depends on clinical pipeline success.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-001951
Document: 9999999995-26-001951-index.html9999999995-26-001951
Document: 9999999995-26-001951.txt9999999995-26-001951

Track record

15 reports on FBRX

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +39.79% at T+60 after the Apr 8, 2026 report. 4 of 6 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry price pending
  2. Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry price pending
  3. Nov 4, 202612d ago SC 13G/A Bearish 4/10 No price data
  4. Sep 2, 202610w ago EFFECT Bearish 7/10 Entry $76.99 settles Nov 27
  5. Sep 2, 202610w ago EFFECT Bearish 6/10 Entry $76.99 settles Nov 27
  6. Aug 27, 202611w ago 25-NSE Bearish 9/10 Entry $76.99 settles Nov 20
  7. Jul 27, 202616w ago 8-K Bullish 8/10 Entry $76.50 No price data
  8. Jun 11, 202622w ago EFFECT Bearish 6/10 Viewing Entry $17.40 No price data
  9. Jun 5, 202623w ago S-3/A Bearish 6/10 Entry $15.67 No price data
  10. Jun 2, 202623w ago S-3 Bearish 6/10 Entry $17.00 to $76.99 ▼ −352.88% −350.38% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens Wed (11h 50m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 11, 2026